Results of Viking Therapeutics’ metabolic disease program exceed all other oral therapies in development in terms of reducing liver fat for nonalcoholic steatohepatitis (NASH) patients, according to Greg Zante, the company’s SVP of finance.

Galmed Pharmaceuticals said patients in a mid-stage trial for the company’s treatment for NASH, a fatty liver disease linked to obesity, showed a statistically significant reduction in liver fat.